Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 9/20 | 0.50 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27934794 | 0.81 | SLC22A16 (0.65) | BBOX1SLC22A16CA1NFKB1CA2 | |
| SCHEMBL3497626 | 0.74 | — | — | |
| SCHEMBL10912369 | 0.74 | GPR84 (0.71) | GPR84BBOX1CA1NFKB1CA2 | |
| SCHEMBL10908925 | 0.74 | GPR84 (0.66) | GPR84BBOX1CA1NFKB1CA2 | |
| Potassium Ion SCHEMBL10911436 | 0.74 | GPR84 (0.66) | GPR84BBOX1CA1NFKB1CA2 | |
| Tetramethylammonium Ion SCHEMBL11559920 | 0.73 | GPR84 (0.86) | GPR84CA1NFKB1CA2 | |
| SCHEMBL465409 | 0.71 | BBOX1 (0.61) | GPR84BBOX1SLC22A16CA1NFKB1 | |
| SCHEMBL10911206 | 0.71 | GPR84 (0.62) | GPR84BBOX1CA1NFKB1CA2 | |
| Potassium Ion SCHEMBL11688990 | 0.71 | GPR84 (0.57) | GPR84BBOX1SLC22A16CA1NFKB1 | |
| Potassium Ion SCHEMBL11729060 | 0.71 | GPR84 (0.79) | GPR84CA1NFKB1CA2FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646508-B1 | Method of safely administering nitrate dietary supplements and compositions | THERMOLIFE INTERNATIONAL, LLC (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646508-B1 | Method of safely administering nitrate dietary supplements and compositions | NOS1, NOS2, NOS3 | GPR84 3445/4885BBOX1 488/4885SLC22A16 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.